Compare BridgeBio Pharma Inc (BBIO) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Sprott Uranium Miners ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Sprott Uranium Miners ETF trades at $55.55. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | URNM | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $90.17 | $83.99 |
52-Week Low | $47.29 | $44.14 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
URNM trades at $54.53, up 2.77% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF, focused on uranium miners, benefits from growing nuclear energy demand driven by AI power needs and government support, as highlighted in recent news. However, key financial ratios like P/E and P/S are unavailable, limiting fundamental clarity.
The outlook for URNM is positive due to structural tailwinds in nuclear energy, but risks include high volatility from commodity prices and concentrated miner exposure. Investors should weigh the bullish technical setup against the lack of transparent valuation metrics and potential sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
